lenalidomide,idecabtagene vicleucel
bms,2seventy bio
['multiple myeloma', 'karmma', 'karmma-2', 'idecabtagene']
insights into dr. ran reshef's study "karmma-2 cohort 2a: efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation" at #ash22. 
Updates on innovations in #cancer research, prevention, care, and education from the Herbert Irving Comprehensive Cancer Center at @columbiamed/@nyphospital.